Your browser is no longer supported. Please, upgrade your browser.
Settings
PZRX PhaseRx, Inc. daily Stock Chart
PZRX [NASD]
PhaseRx, Inc.
Index- P/E- EPS (ttm)-1.19 Insider Own11.22% Shs Outstand11.85M Perf Week-50.00%
Market Cap6.40M Forward P/E- EPS next Y-1.35 Insider Trans0.00% Shs Float10.38M Perf Month-18.18%
Income-13.90M PEG- EPS next Q-0.24 Inst Own51.50% Short Float0.08% Perf Quarter-21.74%
Sales- P/S- EPS this Y-320.20% Inst Trans0.18% Short Ratio0.01 Perf Half Y-48.08%
Book/sh0.19 P/B2.84 EPS next Y-19.50% ROA-152.20% Target Price12.00 Perf Year-66.04%
Cash/sh0.70 P/C0.77 EPS next 5Y- ROE-298.50% 52W Range0.50 - 1.95 Perf YTD-65.16%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-72.31% Beta-
Dividend %- Quick Ratio3.20 Sales past 5Y- Gross Margin- 52W Low7.21% ATR0.19
Employees15 Current Ratio3.20 Sales Q/Q- Oper. Margin- RSI (14)37.41 Volatility20.18% 22.00%
OptionableNo Debt/Eq2.64 EPS Q/Q83.60% Profit Margin- Rel Volume0.57 Prev Close0.55
ShortableYes LT Debt/Eq1.86 Earnings- Payout- Avg Volume1.12M Price0.54
Recom3.00 SMA20-32.15% SMA50-34.34% SMA200-45.97% Volume632,727 Change-2.00%
Oct-16-17Downgrade Laidlaw Buy → Neutral
Dec-11-17 12:35PM  PhaseRx Inc (PZRX) Investors Run for the Hills Following Bankruptcy News SmarterAnalyst -44.90%
11:45AM  [$$] PhaseRx, a Developer of Liver Drugs, Files for Bankruptcy The Wall Street Journal
07:05AM  PhaseRx Commences Voluntary Chapter 11 Bankruptcy Protection Proceeding PR Newswire
Nov-28-17 12:34PM  PhaseRx Inc (PZRX) Stock Rallies on Investor Optimism Over Orphan Drug Designation in the European Union SmarterAnalyst +21.21%
08:30AM  PhaseRx Receives Positive Opinion for Orphan Drug Designation for PRX-ASL from European Medicines Agency PR Newswire
Nov-09-17 08:00AM  PhaseRx Reports Third Quarter 2017 Financial Results and Provides Corporate Update PR Newswire
Nov-03-17 02:49PM  Does PhaseRx Incs (PZRX) Debt Level Pose A Serious Problem? Simply Wall St.
Nov-02-17 08:15AM  Analysis: Positioning to Benefit within Tandem Diabetes Care, CASI Pharmaceuticals, SAExploration, Roka Bioscience, VirnetX, and PhaseRx Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire +6.86%
Oct-31-17 08:00AM  PhaseRx to Present at 5th International mRNA Conference PR Newswire -6.06%
Oct-26-17 06:30PM  PhaseRx Receives Delisting Notice from Nasdaq and Evaluates Listing Options PR Newswire
Oct-17-17 07:10AM  Featured Company News - PhaseRx Announces Cutback in Workforce; Considers Corporate Restructuring ACCESSWIRE -7.34%
Oct-13-17 08:30AM  PhaseRx Announces Corporate Restructuring and Review of Strategic Alternatives PR Newswire +14.12%
Sep-20-17 02:07PM  PhaseRx Receives Orphan Drug Designation from FDA for PRX-ASL for the Treatment of Argininosuccinate Lyase Deficiency PR Newswire +66.45%
Aug-10-17 08:30AM  PhaseRx Reports Second Quarter 2017 Financial Results and Provides Corporate Update PR Newswire
May-12-17 08:30AM  PhaseRx Reports First Quarter 2017 Financial Results and Provides Corporate Update PR Newswire
May-03-17 08:30AM  PhaseRx to Present Data at the American Society of Gene & Cell Therapy 20th Annual Meeting PR Newswire
May-01-17 07:30AM  Today's Research Reports on Stocks to Watch: Cempra and PhaseRx Accesswire
Apr-27-17 04:05PM  PhaseRx to Present Data at the TIDES Conference PR Newswire
Apr-25-17 08:30AM  PhaseRx Receives Positive Opinion for Orphan Drug Designation for PRX-OTC from European Medicines Agency PR Newswire -19.90%
Mar-31-17 01:04PM  PHASERX, INC. Financials
Mar-27-17 11:01AM  PHASERX, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
08:30AM  PhaseRx Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update PR Newswire
Mar-08-17 11:01AM  PHASERX, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Mar-06-17 03:07PM  PHASERX, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Shareholder Direct
Feb-27-17 08:30AM  PhaseRx to Present at Upcoming Investor Conferences PR Newswire +5.60%
Feb-08-17 08:00AM  PhaseRx to Present Data for PRX-OTC at the 13th Annual WORLDSymposium 2017 PR Newswire
Jan-04-17 08:30AM  PhaseRx to Present at Biotech Showcase 2017 PR Newswire
Nov-30-16 09:53AM  PhaseRx Soars on Orphan Drug Status for Rare Liver Disease Zacks -6.25%
Nov-28-16 11:35AM  PhaseRx More Than Doubles on Key FDA Approval 24/7 Wall St. +149.56%
08:41AM  PHASERX, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
08:30AM  PhaseRx Receives Orphan Drug Designation from FDA for PRX-OTC for the Treatment of Ornithine Transcarbamylase Deficiency PR Newswire
Nov-08-16 08:47AM  PHASERX, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
08:30AM  PhaseRx Announces Positive Safety Results from Large Animal Study with Hybrid mRNA Delivery Technology PR Newswire
Nov-07-16 08:46AM  PHASERX, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits -12.20%
08:30AM  PhaseRx Reports Third Quarter 2016 Financial Results and Provides Corporate Update PR Newswire
06:07AM  PHASERX, INC. Files SEC form 10-Q, Quarterly Report
Oct-25-16 08:30PM  PhaseRx to Present at 2016 International mRNA Health Conference PR Newswire
Oct-11-16 11:44AM  PhaseRx, Inc. to Present at The MicroCap Conference on October 24-25 in Philadelphia Accesswire
PhaseRx, Inc., a biopharmaceutical company, engages in developing a portfolio of products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy. The company develops its products based on its proprietary Hybrid mRNA technology platform, which allows the synthesis of missing enzyme inside the cell. Its therapeutic urea cycle disorder programs under development include PRX-OTC to treat ornithine transcarbamylase deficiency; PRX-ASL to treat argininosuccinate lyase deficiency; and PRX-ASS1 to treat argininosuccinate synthetase deficiency. The company was incorporated in 2006 and is headquartered in Seattle, Washington.